

ABSTRACT OF THE DISCLOSURE

The present invention relates to allergy vaccines and methods of treating and/or preventing asthma, and allergic conditions. The invention is based on the discovery that inhibiting the ligand/receptor interactions involving, *e.g.*, IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interferon-alpha, histamine, leukotriene, and their
5 respective receptors, inhibits production of IgE thereby treating or preventing such diseases or conditions. Competitive inhibition of such receptor/ligand interactions is accomplished by immunizing a human or veterinary patient with the interleukin, interferon-alpha, histamine, leukotriene, their receptors, in any combination. Also, the
10 invention relates to inhibiting receptor/ligand interactions involved in IgE production by competitively inhibiting such interactions by administering antibodies to the ligands, receptors, or both, as well as by administering analogs of the receptors (*e.g.*, soluble receptors not associated with a cell).

3311229 "E.C.F. 660